Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lenalidomide in multiple myeloma.

Paul G Richardson1, Constantine Mitsiades, Teru Hideshima

  • 1Jerome Lipper Multiple Myeloma Center, Divison of Hematologic Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. paul_richardson@dfci.harvard.edu

Expert Review of Anticancer Therapy
|August 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimodal immunopharmacologic screens identify drugs rewiring the cancer-immune interface.

bioRxiv : the preprint server for biology·2026
Same author

Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond.

Haematologica·2024
Same author

Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.

Oncogene·2024
Same author

Retraction: Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of β1-Integrin and Phosphatidylinositol 3'-Kinase/AKT Signaling.

Cancer research·2024
Same author

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.

Blood·2023
Same author

MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells.

Journal for immunotherapy of cancer·2023
Same journal

Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.

Expert review of anticancer therapy·2026
Same journal

Barriers to the use of brachytherapy for treatment of cervical cancer and prostate cancer in low- and middle-income countries.

Expert review of anticancer therapy·2026
Same journal

The dual role of Schlafen11 in brain tumors: Jekyll and Hyde.

Expert review of anticancer therapy·2026
Same journal

Central nervous system-related permanent consequences in long-term survivors of pediatric Langerhans cell histiocytosis: a clinical overview and monitoring strategies.

Expert review of anticancer therapy·2026
Same journal

RTsDEN: reverse task attention enabled deep learning model for lung cancer detection using computed tomography.

Expert review of anticancer therapy·2026
Same journal

The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma.

Expert review of anticancer therapy·2026
See all related articles

Lenalidomide (Revlimid) offers a new treatment for relapsed multiple myeloma, showing durable responses and manageable side effects, especially when combined with dexamethasone.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Current multiple myeloma therapies like chemotherapy and stem cell transplant have limited long-term efficacy.
  • Disease progression and resistance necessitate novel therapeutic strategies.
  • Bortezomib and thalidomide represent recent advancements in multiple myeloma treatment.

Purpose of the Study:

  • To review the efficacy and safety profile of lenalidomide (Revlimid) in multiple myeloma.
  • To summarize current clinical evidence supporting lenalidomide's use in relapsed and refractory disease.

Main Methods:

  • Review of clinical trial data and published literature on lenalidomide in multiple myeloma.
  • Analysis of lenalidomide's efficacy, safety, and tolerability, particularly in combination regimens.

Related Experiment Videos

Main Results:

  • Lenalidomide (Revlimid) demonstrates significant clinical response rates in patients with relapsed and refractory multiple myeloma.
  • Combination therapy with lenalidomide and dexamethasone yields durable responses.
  • Lenalidomide is generally well-tolerated with manageable toxicities.

Conclusions:

  • Lenalidomide (Revlimid) is a promising immunomodulatory drug for multiple myeloma treatment.
  • It offers an effective option for patients with relapsed disease, improving remission maintenance.
  • Further evidence supports lenalidomide's role in managing multiple myeloma.